These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
335 related articles for article (PubMed ID: 23075544)
1. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease. Maltais F; Milot J Ther Adv Respir Dis; 2012 Dec; 6(6):345-61. PubMed ID: 23075544 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD. Fuhr R; Magnussen H; Sarem K; Llovera AR; Kirsten AM; Falqués M; Caracta CF; Garcia Gil E Chest; 2012 Mar; 141(3):745-752. PubMed ID: 21903737 [TBL] [Abstract][Full Text] [Related]
3. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Gupta V; Singh D Expert Rev Respir Med; 2012 Dec; 6(6):581-8. PubMed ID: 23234445 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. Beier J; Kirsten AM; Mróz R; Segarra R; Chuecos F; Caracta C; Gil EG COPD; 2013 Aug; 10(4):511-22. PubMed ID: 23819698 [TBL] [Abstract][Full Text] [Related]
5. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. Cazzola M; Page CP; Matera MG Expert Opin Pharmacother; 2013 Jun; 14(9):1205-14. PubMed ID: 23566013 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF; COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Jones PW; Singh D; Bateman ED; Agusti A; Lamarca R; de Miquel G; Segarra R; Caracta C; Garcia Gil E Eur Respir J; 2012 Oct; 40(4):830-6. PubMed ID: 22441743 [TBL] [Abstract][Full Text] [Related]
8. Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease. Jones PW Int J Chron Obstruct Pulmon Dis; 2015; 10():677-87. PubMed ID: 25848244 [TBL] [Abstract][Full Text] [Related]
9. Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review. Jones P Adv Ther; 2013 Apr; 30(4):354-68. PubMed ID: 23553509 [TBL] [Abstract][Full Text] [Related]
10. Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study. Beier J; Mroz R; Kirsten AM; Chuecos F; Gil EG Int J Chron Obstruct Pulmon Dis; 2017; 12():1731-1740. PubMed ID: 28652725 [TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of aclidinium versus glycopyrronium and tiotropium, as maintenance treatment of moderate to severe COPD patients: a systematic review and network meta-analysis. Karabis A; Lindner L; Mocarski M; Huisman E; Greening A Int J Chron Obstruct Pulmon Dis; 2013; 8():405-23. PubMed ID: 24043936 [TBL] [Abstract][Full Text] [Related]
12. NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease. Vogelmeier C; Banerji D Ther Adv Respir Dis; 2011 Jun; 5(3):163-73. PubMed ID: 21511677 [TBL] [Abstract][Full Text] [Related]
13. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. Gavaldà A; Ramos I; Carcasona C; Calama E; Otal R; Montero JL; Sentellas S; Aparici M; Vilella D; Alberti J; Beleta J; Miralpeix M Pulm Pharmacol Ther; 2014 Aug; 28(2):114-21. PubMed ID: 24928173 [TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants. Jansat JM; Lamarca R; de Miquel G; Schrödter A; Miletzki B; Gurniak M J Clin Pharmacol; 2009 Oct; 49(10):1239-46. PubMed ID: 19592595 [TBL] [Abstract][Full Text] [Related]
15. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease. Woods JA; Nealy KL; Barrons RW Ann Pharmacother; 2013; 47(7-8):1017-28. PubMed ID: 23737515 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of aclidinium bromide in patients with COPD: A phase 3 randomized clinical trial in a Korean population. Lee SH; Lee J; Yoo KH; Uh ST; Park MJ; Lee SY; Kim JY; Kim DK; Kim SJ; Lee KH; Yoo CG Respirology; 2015 Nov; 20(8):1222-8. PubMed ID: 26370136 [TBL] [Abstract][Full Text] [Related]
17. An update on the efficacy and safety of aclidinium bromide in patients with COPD. Alagha K; Bourdin A; Tummino C; Chanez P Ther Adv Respir Dis; 2011 Feb; 5(1):19-28. PubMed ID: 20884687 [TBL] [Abstract][Full Text] [Related]
18. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. Joos GF; Schelfhout VJ; Pauwels RA; Kanniess F; Magnussen H; Lamarca R; Jansat JM; Garcia Gil E Respir Med; 2010 Jun; 104(6):865-72. PubMed ID: 20044242 [TBL] [Abstract][Full Text] [Related]
19. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD. Vestbo J; Vogelmeier C; Creemers J; Falques M; Ribera A; Gil EG COPD; 2010 Oct; 7(5):331-6. PubMed ID: 20854047 [TBL] [Abstract][Full Text] [Related]
20. Aclidinium bromide for stable chronic obstructive pulmonary disease. Ni H; Soe Z; Moe S Cochrane Database Syst Rev; 2014 Sep; 2014(9):CD010509. PubMed ID: 25234126 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]